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The CMRF-44 and CD83 (HB15) antigens are associated
with functional maturation and activation of blood dend-
ritic cells (DC). We describe the expression of these
antigens on freshly isolated epidermal Langerhans cells
and dermal DC as well as the distribution of CD83F/
CMRF-44FF-activated DC within sections of normal
human skin. Fresh Langerhans cells were prepared by
standard techniques and large numbers of enriched (25%–
55%), viable dermal DC were obtained using an improved
collagenase treatment protocol with density gradient
enrichment. Freshly isolated Langerhans cells and dermal
DC had similar costimulator and activation antigen
expression, and both stimulated moderate levels of allog-
eneic T lymphocyte proliferation as determined in the
7 d mixed leukocyte reaction. In situ labeling of DC
within skin sections revealed a population of CD83 and
Immunologic surveillance of the skin epithelial surfaces is main-tained in part by the presence of large numbers of professionalantigen-presenting cells at these sites. Langerhans cells are special-ist epidermal antigen-presenting cells with an exceptional abilityto stimulate naı¨ve T lymphocytes (Schuler and Steinman, 1985)
and to present recall antigens to previously activated T lymphocytes
(Cohen and Katz, 1992). In addition, human and murine dermis contain
dendritic cells (DC) that may contribute to the maintenance of cutaneous
immunity (Davis et al, 1988; Lenz et al, 1993; Nestle et al, 1993). Dermal
DC may be identified by their intense HLA class II expression, morpho-
logy, and in vitro migratory capacity, but show heterogenous expression
of CD1a, CD14, CD36, Lag antigens, and factor XIIIa (Davis et al, 1988;
Cerio et al, 1989; Lenz et al, 1993; Nestle et al, 1993; Richters et al, 1994;
Pope et al, 1995; Lukas et al, 1996). Clinically, dermal DC appear to be
involved in the pathology of a number of skin conditions. For example,
dermal DC isolated from psoriatic skin show increased autostimulation
of T lymphocytes (Nestle et al, 1994), and dermal DC, but not Langerhans
cells, were reported to be important in the clearance of the Lyme disease
causative organism Borellia burgdorferi from human skin (Filgueria et al,
1996). Dermal DC may also contribute to HIV transmission (Pope
et al, 1994).
We have analyzed the distribution and activation status of Langerhans
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CMRF-44 positive dermal cells of which most (µ75%)
were in intimate contact with CD3F T lymphocytes,
especially in the adnexal regions. In contrast, only 25%–
30% of the more numerous CD1aFF dermal DC popula-
tion were directly apposed to T lymphocytes. The CMRF-
44FF dermal DC population stimulated an allogeneic
mixed leukocyte reaction, confirming their identity as
DC. These data, plus comparative data obtained for
migratory dermal DC, suggest that only a small propor-
tion of dermal DC have been triggered to a more
advanced state of differentiation or activation. The strik-
ing association of the activated dermal DC population
with T lymphocytes suggests that communication
between these two cell types in situ may occur early in
the immune response to cutaneous antigen. Key words:
CD83/CD86/CMRF-44/dermis. J Invest Dermatol 111:841–
849, 1998
cells and dermal DC in normal skin using the monoclonal antibodies
(MoAb) CMRF-44 and CD83. These two MoAb recognize different
antigens, which are expressed during the functional maturation of fresh
DC into potent allostimulatory antigen-presenting cells (Zhou et al,
1992; Hock et al, 1994; Zhou and Tedder, 1995; Fearnley et al, 1997).
Fresh blood DC do not express CD83 and only a subpopulation is
weakly positive for CMRF-44; however, the expression of both these
DC-associated antigens is rapidly upregulated on blood DC following
a period of in vitro culture (Fearnley et al, 1997; Zhou et al, 1992;
Zhou and Tedder, 1995). Low density expression of the CD83 and
CMRF-44 antigens can be induced on blood monocytes by stimuli
such as interferon or ionophore treatment and also on lymphocytes by
mitogens or Ig cross-linking (Zhou et al, 1992; Hock et al, 1994;
Czerniecki et al, 1997; and our unpublished data). High density
expression of CD83 and CMRF-44 is found on cultured blood DC
and these markers have proved to be valuable for identifying activated/
differentiated DC in kidney (Troy et al, 1998a) and prostate (Troy
et al, 1998b) cancers. Although the upregulation of the CMRF-44 and
CD83 antigens on blood DC correlates with increased levels of the
costimulatory antigens CD40, CD80, and CD86 (McLellan et al,
1995a, 1996), neither the CMRF-44 nor the CD83 MoAb influence
T lymphocyte activation and at present the function of these molecules
is unknown (Zhou and Tedder, 1995; Fearnley et al, 1997).
We show here that the majority of activated (CMRF-4411 or
CD831) dermal DC are in intimate contact with T lymphocytes in
normal skin. This finding suggests that communication between these
two cell types in situ may occur early in the immune response to
cutaneous antigen.
MATERIALS AND METHODS
Monoclonal antibodies The CMRF-44 (IgM; Hock et al, 1994), CD14
(CMRF-31; IgG2a), and negative control MoAb CMRF-75 (IgM) were
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produced in this laboratory. CD1a (Na1/34; IgG2a) was a gift from Prof. A.
McMichael (Oxford, U.K.). CD3 (OKT3; IgG2a), CD8 (OKT8; IgG2a),
CD25 (7G7; IgG2a), CD45RO (UCHL1; IgG2a), and anti-HLA-DQ (L227;
IgG1) supernatants were produced from hybridomas obtained from the American
Type Culture Collection (Manassas, VA). Fluoresceinated HLA-DQ MoAb
(L227) was prepared by incubating 1 mg of protein-A (Sigma, St Louis, MO)
purified MoAb at 1 mg per ml in 0.1 M borate (pH 8.5) with 30 µl of 10 mg
fluorescein-isothiocyanate (FITC; Isomer I; Sigma) per ml in dimethylsulfoxide
for 1 h at room temperature. Excess FITC was removed by Centricon-100
(Amicon, Beverly, MA) dialysis. CD80 (L307; IgG1), phycoerythrin (PE)-
conjugated anti-HLA-DR (IgG2a), CD86-PE (BU63; IgG1), and PE-conjug-
ated isotype controls were purchased from Becton Dickinson (San Jose, CA).
Quantum Red (QR) conjugated HLA-DR was from Sigma. Unconjugated
BU63 (CD86; IgG1) was kindly provided by Dr. D. Hardie (University of
Birmingham, Birmingham, GB), and HB15a (CD83; IgG2b) was kindly
provided by Prof. T.F. Tedder (Duke University, Durham, NC) and from
Coulter (Hialeah, FL). The isotype control MoAb X63 (IgG1) producing
hybridoma was obtained from the American Type Culture Collection and Sal-
4 (IgG2b) was from Dr. Leonie Ashman (IMVS, Adelaide, Australia). Fluorescein
isothiocyanate-conjugated sheep anti-mouse-immunoglobulin (FITC-SAM-Ig)
was obtained from Silenus Laboratories (Hawthorn, Australia).
Immunohistology Human skin was obtained from reduction mammoplasty
specimens with ethical permission from the Southern Regional Health Authority
Ethical Committee.
Cryostat cut en face sections (7 µm) of the epidermis and upper dermis of
normal human breast skin mounted in Tissue-Tek OCT (Miles, Elkhart, IN)
were placed onto gelatin-coated glass slides and allowed to dry overnight. The
sections were fixed for 10 min in ice cold acetone and air dried for 30 min.
Sections were then blocked with 10% human serum/phosphate-buffered saline
(PBS) prior to reaction with primary MoAb followed by biotinylated goat anti-
mouse Ig (1/200 dilution; DAKO, Carpinteria, CA) and then addition of 1/
200 streptavidin-alkaline phosphatase (Sigma). Slides were washed three times
with TBS between each 30 min incubation. Enzymatic activity was revealed
with Fast Blue substrate solution: 2 mg sodium AS phosphate dissolved in
100 µl dimethyl formamide, 10 mg fast blue salt, 6 µl 1 M levamisole (all from
Sigma), and 10 ml 0.1 M Tris pH 8.2. For double immunoenzyme labeling,
the sections were reacted with the second MoAb, followed by peroxidase
conjugated goat anti-mouse Ig (1/100; DAKO). The substrate used for detection
of the second MoAb was 3-amino-9-ethyl cabazole (AEC) (10 mg AEC; Sigma,
first dissolved in 100 µl of DMF, then in 10 ml of 0.05 M acetate pH 5.1 with
6 µl of H2O2).
Cell density was estimated by counting labeled cells in a tissue section area
of normally at least 2 mm2, with an eyepiece graticule of known area at 2003
magnification. For in situ analysis of the percentage of dermal DC apposition
to T lymphocytes, dermal DC were scored as clustered if part of the stained
dermal DC membrane contacted at least one T lymphocyte. Slides were
photographed on Kodak Gold 100 ASA film using an Olympus BX-50 equipped
with a PM-30 camera system.
Medium and cell preparation Cell culture medium used throughout the
study was RPMI-1640 supplemented with 100 U penicillin per ml, 100 µg
streptomycin per ml, 2 mM L-glutamine, 25 mM HEPES (pH 7.4), and either
10% heat inactivated fetal calf serum for DC isolation and culture (Life
Technologies, Auckland, NZ), or 10% pooled AB serum for the mixed
lymphocyte reaction (MLR).
Langerhans cell preparation Epidermal sheets were prepared from split
thickness human breast skin by overnight Dispase II (0.5% in PBS; Boehringer,
Mannheim, Germany) digestion at 4°C for cell labeling studies, or for 1 h at
37°C for some of the functional studies. The epidermis was minced by scissor
action with scalpels and digested for 20 min with 0.25% trypsin (Sigma) and
DNase I (5 U per ml, Sigma) in PBS at 37°C. Epidermal fragments were then
disaggregated by vigorous pipetting and passage through a cell dissociation cup
(grade 40 mesh; Sigma). The cells were immediately collected into HEPES
buffered RPMI/fetal calf serum. Following nylon mesh filtration (80 µm;
Millipore, Bedford, MA), cell suspensions were washed twice in RPMI/10%
fetal calf serum/DNaseI with DNase I, resuspended in RPMI/10% fetal calf
serum/DNaseI and Langerhans cells enriched by up to three sequential
Lymphoprep gradients (Pharmacia, Auckland, NZ) as described by Peguet-
Navarro (1995). Langerhans cells were typically enriched from 1% to 2%
(following trypsinization) to 4%–11% (as determined by HLA-DR labeling)
after the first Lymphoprep gradient purification. Cell suspensions obtained
following the second (22%–32% Langerhans cells) or third (28%–45% Langerhans
cells) Lymphoprep were used for most experiments.
In some experiments, Langerhans cells enriched epidermal cell suspensions
were cultured in medium at 5 3 106 cells per ml in 24 well plates (Nunc, Life
Technologies, Auckland, NZ) for 40 h prior to immunofluorescence analysis.
For reverse transcriptase-polymerase chain reaction analysis, fresh Lymphoprep
enriched Langerhans cells were further purified by sorting of the HLA-
DR111 fraction on a FACS Vantage (Becton Dickinson). Reverse transcriptase-
polymerase chain reaction was performed as previously described (McLellan
et al, 1995a). All Langerhans cell enriched populations used in this study
for reverse transcriptase-polymerase chain reaction were greater than 75%
HLA-DR111.
Dermal DC preparation Fresh dermal DC were prepared from split
thickness normal human breast skin following overnight Dispase digestion at
4°C and meticulous removal of all epidermis. The split thickness dermal sheets
were minced by scissor action with scalpels into 0.5–2 mm2 pieces and partially
digested with 1.0 mg collagenase (trypsin free, type D, Boehringer) per ml and
DNase I, in 20–30 ml of RPMI-1640/fetal calf serum with 25 mM HEPES
(pH 7.3) in a Petri dish with gentle swirling for 1 h at 37°C. Shorter collagenase
digestion times (30 min) failed to release detectable leukocytes, and longer
collagenase treatment (2–3 h) resulted in contamination of dermal cell prepara-
tions with many CD45– cells (data not shown). Undigested tissue was removed
by 80 µm screen filtration and a large wash volume (10–20 volumes of bovine
serum albumin/DNase I/PBS) was required to pellet the cells from the viscous
cell suspension. Following a second wash in 100 ml and 60 µm mesh filtration,
dead cells, debris and some contaminating fibroblasts were removed by
Lymphoprep gradient separation (ρ 5 1.077 g per cm3, 10 min, 500 3 g).
Migratory dermal DC Migratory DC were isolated from cultured dermis
using standard techniques (Lenz et al, 1993; Nestle et al, 1993), originally
described for murine split skin explants by Larsen et al (1990). Briefly, the
epidermis was removed from Dispase treated split thickness skin and the dermis
chopped into µ1–2 mm3 fragments and cultured in RPMI/10% fetal calf serum
with 25 mM HEPES (pH 7.4) in Petri dishes at 37°C, 5% CO2. Medium
acidification was minimized by replacing up to half of the medium after 24 h.
Migratory dermal cells were obtained at day 2 as a cell suspension following
removal of the dermal fragments by 80 µm nylon gauze filtration. In most
experiments, dermal DC were enriched to 80%–90% using a hypertonic
Nycodenz gradient (Nycoprep; ρ 5 1.068; generous gift from Nycomed-
Pharma, Oslo, Norway), as described for the isolation of mature blood DC
(McLellan et al, 1995b).
Immunolabeling for flow cytometric analysis and sorting Cells were
labeled with saturating concentrations of primary MoAb for 30 min on ice
and incubation with FITC-SAM-Ig. Following primary staining, cells were
incubated in 10% mouse serum/PBS for 5 min, labeled with FITC-, PE-, or
QR-conjugated MoAb for 30 min, and then analyzed on a FACS Vantage
using Cellquest software.
For flow cytometric analysis or sorts of both Langerhans cells and dermal
DC, gates were set to include cells with high forward scatter and moderate to
high side scatter. These gates excluded small lymphocytes and debris as well as
dead cells as confirmed by propidium iodide labeling.
Allogeneic MLR Graded doses of mitomycin C treated dermal DC or
Langerhans cells were cultured with 105 allogeneic ER1 T lymphocytes
(prepared by ammonium chloride lysis of neuraminidase treated sheep red blood
cell rosettes of peripheral blood mononuclear cells) in a final volume of 200 µl
of HEPES buffered RPMI-1640 with 10% heat inactivated AB serum in round
bottom 96 well plates (Falcon/Becton Dickinson, Franklin Lakes, NJ). After 5
or 7 d of culture at 37°C in 5% CO2, cultures were pulsed with 1 µCi
[3H]thymidine (Amersham International, Arlington Heights, IL) per well for
the final 19 h before harvesting and liquid scintillation counting. All assays were
performed in triplicate.
RESULTS
DC differentiation/activation antigen expression on fresh
Langerhans cells Flow cytometric analysis of Lymphoprep enriched
Langerhans cells (n 5 4) indicated weak to moderate expression of
the CMRF-44, CD83, and CD86 antigens on either a subpopulation
or all of the strongly HLA-DR111/CD1a111 positive Langerhans
cells (Fig 1a). CD80 expression on Langerhans cells was either very
weak or absent, although we were able to detect CD80, as well as
CD86 mRNA transcripts, in sorted fresh Langerhans cells and culture
of fresh Langerhans cell-induced CD80 surface expression (data not
shown).
We found that 65%–90% of the Langerhans cells present in the
pregradient trypsinised cell suspension were lost into the pellet fraction
during the gradient isolation procedure. To ensure that the activation
antigen expression on the gradient enriched Langerhans cell preparations
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Figure 1. Flow cytometric analysis of activation and
costimulatory antigens on fresh Langerhans cells, fresh
dermal DC, and 2 d migratory dermal DC. Contour plots of
(a) fresh Langerhans cells, (b) gradient enriched dermal DC
following collagenase release (DDC), or (c) migratory dermal DC
(mDDC) labeled with the indicated MoAb and FITC-SAM
(horizontal axis) and HLA-DR-PE (vertical axis). The quadrant
gates were set to contain .98% of negative control labeled
cells. Ig con, representative negative control. The results are
representative of at least three experiments performed.
was representative of total Langerhans cells, we also labeled unfraction-
ated trypsinised epidermal cell suspensions. The results were similar:
22%–55% of HLA-DR positive cells expressed the CMRF-44 antigen
prior to gradient isolation, versus 40%–75% after gradient isolation
(n 5 2).
Isolation and initial characterization of fresh dermal
DC Dermal DC were prepared using low tryptic activity collagenase
digestion for 1 h prior to a single density gradient enrichment of
dermal DC. The forward and side scatter plots of dermal cell suspensions
(with CD451 cells backgated) obtained after collagenase treatment and
following a single Lymphoprep density cut are shown in Fig 2. The
typical positioning of myeloid and lymphoid gates used in this study
for flow cytometric analysis of dermal cell suspensions are also shown
in Fig 2.
The resulting cell suspensions (5.4 3 106 cells 6 4.9 3 106 SD,
range 1–12 3 106 per experiment, n 5 20) were enriched in HLA-
DR111/CD1a11 dermal DC (Fig 1b; 41% 6 10% SD, range 25%–
55%, n 5 15) and effectively depleted of strongly CD14 positive tissue
macrophages, despite an apparent abundance of these cells in the dermis
enumerated by immunohistologic staining (see later); however, a small
HLA-DR111/CD1a–/1 subpopulation (,10%) of dermal cells showed
Figure 2. Forward and side scatter dot plots of dermal cells obtained
either (a) directly following 1 h collagenase digestion or (b) following
a single Lymphoprep density gradient cut. CD451 leukocytes were
backgated and are shown as black dots against total cells as gray dots. The
typical positioning of myeloid and lymphoid gates used for size gating for flow
cytometric analysis in this study are shown in (b).
very weak CD14 staining, similar to migratory dermal DC populations
(Nestle et al, 1993, and data not shown). Control studies showed that
CD14 antigen expression was not altered by 1 h collagenase treatment
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Figure 3. MGG-stained cytospins of gradient-enriched collagenase
released dermal mononuclear cell suspensions showing (a) cells
displaying typical DC morphology, (b, c) vacuolated myeloid cells,
probably macrophages, with multiple long cytoplasmic processes and
often containing ingested melanin granules (c; arrow), (d) small dermal
cells with typical lymphocyte morphology, and (e) fresh, activated
dermal cells sorted for high density CMRF-44 expression. A melanophage
present in the CMRF-4411 fraction (e) is arrowed. Scale bar: 10 µm.
of peripheral blood mononuclear cells (data not shown). Although
µ50% of dermal cells were lost into the pellet during the Lymphoprep
gradient step, further labeling analyses confirmed that the gradient
isolated dermal DC showed a surface phenotype representative of the
whole population prior to this step (data not shown).
Some lymphocytes were also included in these preparations (µ10%
of dermal cells) and flow cytometry analysis showed these to be mainly
CD41 or CD81 T lymphocytes (data not shown). DC:T lymphocyte
conjugates, although numerous in cultured migratory dermal DC
preparations (Pope et al, 1995, and data not shown), were not observed
in the hemocytometer directly following collagenase isolation.
Morphologically, many of the dermal DC had myeloid features with
oval or slightly indented nuclei, moderate basophilic cytoplasm, minimal
or no granulation, and a ruffled cell surface (Fig 3a), typical of short-
term cultured blood DC (Hart, 1997). Larger, more vacuolated dermal
cells with typical macrophage morphology were also present (Fig 3b),
some of which contained ingested melanin granules (Fig 3c; arrow).
Numerous small lymphocytes found in fresh collagenase-released dermal
cell preparations are also shown (Fig 3d). Using this isolation method,
we were able to obtain consistent yields of 2–5 3 105 leukocytes per
cm2 of dermis (n 5 15).
Alloantigen presentation by fresh dermal DC The ability of
freshly isolated mitomycin C-treated dermal DC to stimulate the
proliferation of allogeneic peripheral blood T lymphocytes was next
determined. Only minimal T lymphocyte proliferation occurred at day
5 and in five of six experiments an additional 2 d of MLR coculture
led to large increases (relative maximal CPM increase; 83% 6 85%
SD, n 5 6) in allogeneic T lymphocyte proliferation (Fig 4a). Similar
results were obtained using Langerhans cells isolated from the same
donors (relative maximal CPM increase; 88% 6 95% SD, n 5 6,
Fig 4b). In contrast, migratory dermal DC, isolated after 2 d culture
of dermis by Nycodenz gradient separation, stimulated very high levels
of allogeneic T lymphocyte proliferation at both day 5 and day 7
(Fig 4c, n 5 3). Control studies showed that similar handling and
collagenase treatment of peripheral blood mononuclear cell suspensions
did not affect their allostimulatory function in the MLR (data not
shown).
DC differentiation/activation antigen expression on fresh
dermal DC Dermal DC-enriched suspensions were labeled for the
CMRF-44 or CD83 DC differentiation/activation antigens or the
CD80 and CD86 costimulatory antigens (FITC) followed by double
labeling with HLA-DR-PE to identify dermal DC. Isolated dermal
DC showed an activated phenotype as determined by their weak to
moderate expression of the CD83 and CMRF-44 differentiation/
activation antigens. The CMRF-4411 subset expressed slightly higher
levels of HLA-DR antigens than did the CMRF-44– subset. The
costimulatory molecule CD86, but not CD80 (Fig 1b), was present
on the surface of fresh dermal DC. Migratory DC demonstrated
moderate and homogenous expression of the CD83 and CD86 antigens,
with marked upregulation of the CMRF-44 and CD80 antigens clearly
visible on all of the class II positive dermal DC (Fig 1c, n 5 4). The
majority of both the fresh and the migratory dermal DC were
moderately positive for CD1a (CD1a11), although a subpopulation of
HLA-DR bright dermal DC lacked detectable levels of surface CD1a
(Fig 1b, c). No CD1a111 (bright) dermal population labeling with
the similar intensity as the Langerhans cells isolated from the same
donors was observed (cf. Fig 1a with Fig 1b, c), suggesting that these
cells, noted by immunohistologic techniques (Davis et al, 1988), were
either lost during preparation or downregulated their expression of
CD1a antigen.
Triple labeling experiments indicated that in most cases, the majority
of CMRF-44 (66% 6 8% SD, range 58%–77%), CD83 (87% 6 8%
SD, range 75%–92%), or CD86 (93% 6 9% SD, range 80%–100%)
positive, HLA-DR111 gated fresh dermal DC coexpressed moderate
levels of the CD1a antigen. A representative experiment (n 5 4) is
shown (Fig 5). In additon, the CMRF-44, CD83, and CD86 antigens
were expressed at similar intensities on both the CD1a11 and the
minor CD1a– dermal DC subsets (Fig 5).
Morphology and alloantigen presenting ability of isolated
CMRF-44 positive dermal cells The morphology of the activated
CMRF-4411/CD831 dermal cell population was next determined by
flow cytometric sorting of fresh dermal cells for high density CMRF-
44 expression. As shown in Fig 3(e), CMRF-4411 dermal cells were
rounded, often with lobulated nuclei and short cytoplasmic dendritic
processes, similar to the appearance of short-term cultured CMRF-44
positive blood DC. Some CMRF-4411 cells had ingested melanin
(Fig 3e; arrow).
When myeloid gated dermal cells were sorted by flow cytometry
into high purity CMRF-4411 and CMRF-44– subsets, the CMRF-44
positive subset was found to provide significantly greater allostimulatory
activity than the CMRF-44– subset (n 5 3). Direct comparison of the
allostimulatory activity of CMRF-44 positive and negative (class II
positive) dermal DC was determined by further double labeling sorting
experiments. Dermal DC were sorted into HLA-DQ11/CMRF-
4411 and HLA-DQ11/CMRF-44– subsets by flow cytometry and
cocultured in graded doses with allogeneic T lymphocytes. The
CMRF-4411 subset of HLA-DQ11 dermal DC stimulated a slightly
greater allogeneic MLR than the CMRF-44– subset in one case
(Fig 4d), but similar levels of stimulation were noted in two other
experiments. The difficulties involved in obtaining sufficient unequi-
vocally CMRF-44– dermal DC (Fig 1b), due to an apparent in vitro
induction of CMRF-44 expression on the unactivated DC by the
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Figure 4. Allogeneic MLR stimulatory
capacity of dermal and epidermal DC.
(a–c) [3H]Thymidine uptake (y-axis; mean
6 SD) by T lymphocytes stimulated for 5 d
(u) or 7 d (d) by (a) collagenase-released
gradient-enriched dermal cells (fDDC), (b)
fresh Langerhans cells (fLC), or (c) 2 d
migratory dermal DC (mDDC). (d)
Allostimulatory activity of HLA-DQ11/
CMRF-4411 (d) or HLA-DQ11/CMRF-
44– dermal DC (u), sorted by flow cytometry,
as determined in the 7 d MLR. For (a), (b),
and (c), the y axis stimulator numbers were
adjusted to show approximate numbers of
HLA-DR111 positive dermal DC or
Langerhans cells per well, as determined from
flow cytometric analyses. Representative of
at least three experiments performed.
Figure 5. Co-expression of CD1a with CMRF-44, CD83, or CD86 on
HLA-DR111 gated dermal DC. Collagenase-released gradient-enriched
dermal DC populations were labeled with the MoAb indicated, followed by
FITC-SAM (horizontal axis) and counterstained with CD1a-PE (vertical axis)
and HLA-DR-QR (not shown). Contour plots were generated by gating
myeloid sized, strongly HLA-DR positive cells. Representative of four
experiments performed. neg con, negative control.
isolation method (see Discussion), precluded more extensive comparat-
ive studies.
In situ labeling of skin DC subsets As freshly isolated blood DC
rapidly upregulate CMRF-44, CD83, and CD86 after short periods
of in vitro culture (McLellan et al, 1995a; Zhou and Tedder, 1995;
Fearnley et al, 1997), it was possible that expression of these activation
antigens on dermal DC and Langerhans cell suspensions was induced
during the isolation method. We therefore undertook immunohistol-
ogic studies to assess the in situ phenotype of dermal DC and
Langerhans cells.
Epidermal DC Occasional CD83 and very rare CMRF-44 positive
epidermal Langerhans cells were observed in tangential skin sections
of normal breast skin (,1 linear mm of epidermis); however, very
faint labeling of CD83 but not CMRF-44 was noted on most epidermal
CD1a positive cells using immunofluorescence (data not shown). As
previously shown (Davis et al, 1988), CD1a positive Langerhans cells
are present at µ26 per linear mm of normal epidermis. Therefore, as
assessed by in situ immunoenzyme techniques, the majority of epidermal
CD1a positive Langerhans cells do not express the DC CD83 and
CMRF-44 activation antigens.
Dermal DC Strongly HLA-DR positive cells were present in high
density in the upper dermis (306 per mm2 6 104 SD, n 5 4) as
determined from single labeling experiments. To estimate the density
of total dermal DC populations, CD14 positive tissue macrophage
were excluded from these counts by reacting the skin sections with
CD14 MoAb and Fast Blue substrate, prior to HLA-DR/AEC staining.
We were then able to estimate an upper dermis DC density of 114
cells per mm2 6 63 SD (n 5 3).
Despite the high number of cells identified by HLA-DR labeling,
only low numbers of both CMRF-44 (14 per mm2 6 18 SD, n 5 6;
Figs 6b, 7) and CD83 (9 per mm2 6 5 SD, n 5 5; Figs 6c, 7) positive
cells were detected in the dermis. CMRF-44 and CD83 positive cells
were often found adjacent to dermal adnexae and also in the perivascular
areas. The density of CMRF-44 (3 per mm2 6 2 SD, n 5 4, and to
a lesser extent CD83 (6 per mm2 6 7 SD, n 5 4), positive cells in
the dermis was reduced by prior CD14/Fast Blue labeling. Therefore,
although CD83 appears to show little reactivity with CD14 positive
dermal cells, CMRF-44 appears to label a small population (,3%) of
CD14 positive dermal DC or macrophages (Fig 7).
The number of CD1a positive dermal DC (mean 160 per mm2 6 129
SD, n 5 8) in the same regions was µ10–20 fold higher than the
number of CMRF-44 or CD83 positive cells (Fig 7). The CD1a
positive subset contained the majority of CD831 cells, as determined
by double labeling immunofluorescence (n 5 3 donors; data not
shown), consistent with our flow cytometric analysis (Fig 5).
We also examined the expression of CD80 and CD86 on dermal
DC in normal dermis. Only one of four donors showed reaction with
CD80 MoAb (at .1 cell per mm2). Larger numbers of CD86 positive
cells (mean 12 per mm2 6 11 SD, n 5 4) were found (Figs 6, 7). CD86
was present on a minor population of CD141 dermal macrophages as
prior reaction of the sections with CD14 MoAb and fast blue reduced
the numbers of visible CD86 positive cells (Fig 7); however, a
population of CD86 positive/CD14– dermal DC (Fig 6d; mean 6 per
mm2 6 3 SD, n 5 3) was also clearly identifiable.
Distribution of activated dermal DC in relation to T lympho-
cytes within normal human dermis Double labeling analysis with
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Figure 6. Differentiation/activation
antigens on dermal dendritic cells.
Double immunohistochemical labeling of
tissue macrophage (CD14, blue, first MoAb)
with papillary dermal DC populations
(arrowed, red, second MoAb) in en face
sections of normal human skin labeled for (a)
HLA-DR, (b) CMRF-44, (c) CD83, and (d)
CD86. Scale bar: 10 µm. Data are from 3–8
different breast specimens.
Figure 7. Leukocyte counts in the upper dermis. Density of CD14 positive
macrophages, CD1a and HLA-DR positive DC, as well as activated CMRF-
44, CD83, and CD86 positive DC as assessed by immunohistochemical analysis
of the upper dermis of normal human breast skin. Total (j) or CD14 negative
(u) counts are plotted as means of 3–8 different donors expressed as leukocytes
per mm2.
CD3 or CD8 revealed that most of the CMRF-44 or CD83 positive
dermal cells were in intimate contact with dermal T lymphocytes. A
large proportion (µ75%) of CMRF-44 and CD83 positive dermal
cells showed membrane abutment to T lymphocytes (detected with
either CD8 or CD3) surrounding dermal follicles, the perivascular
regions, and periadnexal areas (Fig 8a–d, Fig 9). The expression of
CD86 on large dermal cells was also associated with T lymphocyte
membrane contact. Further analysis showed that CMRF-44 and CD83
positive dermal cells were associated with CD25 receptor (p55) positive
lymphocytes (Fig 8e, f) and with CD45RO positive lymphocytes,
especially lining the sebaceous and periadnexal regions (Fig 8g, h).
Only a minority (25%–30%) of dermal CD1a positive DC identified
were in contact with dermal T lymphocytes (Fig 9). Many of these
‘‘free’’ CD1a positive cells exhibited round nondendritic morphology as
previously described (Weber-Matthiesen and Sterry, 1990). Therefore,
although CD83 and CMRF-44 positive dermal cells are present in the
dermis at µ1/10–1/20 that of the larger CD1a positive subset, there
is preferential expression of the DC activation antigens CMRF-44 and
CD83 on dermal cells in contact with both CD4 and CD8 T
lymphocytes. These cells also express the costimulator molecule CD86.
DISCUSSION
In this study we have examined DC differentiation/activation antigen
expression on epidermal and dermal DC. We used flow cytometric
analysis of freshly isolated Langerhans cells and dermal DC combined
with in situ labeling in order to minimize culture induced changes in
DC phenotype and function.
Fresh dermal DC isolation and characterization The dermal DC isolation
method used in this study relies on the effective rapid release and
survival of DC following enzymatic treatment of the dermis. Therefore,
there remains a possibility that a distinct subset of dermal DC might
not survive release from the dermal matrix or may remain trapped in
the partially digested dermal fragments. Interestingly, these collagenase
released dermal DC populations included similar proportions of dermal
DC delineated by CD1a and CD14 staining as described for migratory
DC preparations (Nestle et al, 1993).
This preparation method is likely to influence DC activation antigen
expression less than when dermal DC are isolated following migration
from the dermis during 1–5 d of in vitro culture. The surface phenotype
of DC is profoundly sensitive to in vitro culture (Romani et al, 1989;
O’Doherty et al, 1993; Thomas et al, 1993a, b; McLellan et al, 1995a)
and the absence of CD80 expression on the fresh dermal DC described
here, as compared with the CD80 positive migratory dermal DC
described here and by others (Nestle et al, 1993; Lenz et al, 1993; Pope
et al, 1995), almost certainly reflects differences in the isolation
procedures used.
Our method is similar to a murine and human dermal DC isolation
method (Tse and Cooper, 1990; Meunier et al, 1993; Sepulveda-
Merrill et al, 1994); however, the shorter collagenase digestion period
used in this study gave high yields of viable dermal mononuclear cells
(0.1–1 3 107 per experiment). These cell suspensions proved to be a
rich source of DC (25%–55% DC) as determined by HLA-DR and
CD1a expression as well as morphologic appearance. Dermal cells with
typical macrophage morphology, as well as T lymphocytes, were also
isolated by this method. Fresh dermal DC stimulated moderate levels
of allogeneic T lymphocyte proliferation in a 7 d, but not 5 d, MLR.
In contrast, a 5 d MLR assay was sufficient for the induction of high
levels of T lymphocyte proliferation by 2 d migratory dermal DC
(compare Fig 4a and c). These data suggest that culture of dermal DC
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Figure 8. Co-localization of activated DC
with T lymphocytes in the upper dermis.
Co-localization of CMRF-441 (a, c, e) and
CD831 (b, d, f) dermal cells (red) with CD31
T lymphocytes (blue) in the upper dermis (a,
b), in periadnexal regions (c, d) and with
CD251 lymphocytes (blue) also in
periadnexal regions (e, f). Co-localization of
CMRF-441 dermal DC (blue) with
CD45RO1 lymphocytes (red) lining a
sebaceous gland (g) and surrounding a hair
follicle (h). The order of addition of the
MoAb is given in the bottom left of each
plate (first MoAb was revealed with fast blue,
second with red AEC). Note that the first
and second MoAb were reversed in (g) and
(h) to avoid reaction of CD45RO with dermal
DC. Scale bar: 10 µm. Data are from 3–7
different breast specimens.
is in itself sufficient stimulus for their development into potent antigen-
presenting cells. This contrasts with freshly isolated blood DC, which
are effective stimulators in a 5 d allogeneic MLR, without an initial
period of DC culture (Thomas et al, 1993a; McLellan et al, 1995a),
despite possessing an immature surface phenotype compared with
dermal DC (O’Doherty et al, 1993; Thomas et al, 1993b).
Dermal DC activation antigen expression Our flow cytometric analysis
showed that 30%–100% of fresh dermal DC had weak to moderate
expression of the CMRF-44, CD83, and CD86 antigens; however,
only a small percentage (µ5%–10%) of total CD14–/HLA-DR111
dermal DC expressed the CMRF-44 and CD83 antigens in sufficient
density for detection by in situ immunohistologic staining. Using
double labeling of dermal cell suspensions (Fig 5) and direct immuno-
fluorescence (data not shown), it was found that the majority of
activated CMRF-4411/CD831 dermal cells were contained within
the CD1a positive subset of dermal DC.
The CMRF-44, CD83, and CD86 antigens were also present on
isolated Langerhans cells, but again these antigens were not readily
detectable on epidermal Langerhans cells using immunohistologic
techniques. Weak expression of CD83 was also observed on the
majority of dermal and epidermal DC in tissue sections using immuno-
fluorescence (data not shown). The relative insensitivity of the immu-
nohistologic method employed, which allowed anatomical localization,
compared with the more sensitive immunofluorescence and flow
cytometric analyses, may explain this apparent discordance. It is also
very likely, however, that some induction or unmasking of these
antigens occurred during DC isolation, given the rapid induction of
CD83 and CMRF-44 on fresh blood DC (Fearnley et al, 1997). An
analogous induction of HLA-class II antigens has been described during
the process of fresh Langerhans cells isolation (Mommaas et al, 1995).
It is also possible that the CD1a antigen undergoes downregulation on
some cells during this activation process given the absence of a discrete
Langerhans cell CD1a bright population in isolated dermal DC.
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Figure 9. Co-localization of activated DC with T lymphocytes in the
upper dermis. The association of CD1a, CMRF-44, CD83 positive, and
CD86 positive dermal cells with T lymphocyte populations identified by CD3
(j) or CD8 (u) staining was qualified. The percentage of total dermal cells
showing direct membrane abutment to T lymphocytes are plotted as mean
values observed in 3–7 different breast skin specimens.
Activated dermal cells, which expressed high levels of the CMRF-
44 and CD83, were readily identifiable lining the vasculature in the
upper dermis and were also commonly associated with T lymphocytes
in the skin adnexae, particularly lining the margins of sebaceous glands
surrounding the hair follicles. It proved difficult to isolate HLA class
II positive CMRF-44– dermal DC, without activation during their
preparation, to a CMRF-4411 phenotype. Thus we were unable to
test the hypothesis rigorously that these would have a different function
to the CMRF-4411 subset of dermal DC. The isolation of CMRF-
44– DC almost certainly led to some in vitro DC ‘‘catch-up’’ differenti-
ation, and this population showed variable allostimulatory activity.
Further experiments to investigate the potential functional differences
between these two subsets will be challenging but of great interest.
Interestingly, migratory dermal DC showed even greater allostimula-
tory activity, suggestive of an active differentiation/activation process
that influences the function of these cells.
Origin of the activated dermal DC subset CMRF-4411/CD831-activ-
ated dermal DC could be derived from the epidermis or the blood.
The finding that activated dermal DC and T lymphocytes were not
randomly distributed but were preferentially associated with sebaceous
glands and hair follicles makes it seem unlikely that these aggregates
have formed from migrating epidermal Langerhans cells. Although
Langerhans cells enter the dermis, they generally form distinct cords
of migrating Langerhans cells within dermal lymphatic vessels. These
structures are only detectable following in vitro culture of skin explants
(Lukas et al, 1996), skin transplant or systemic TNFα, IL-1, or LPS
administration in mice (Larsen et al, 1990; Roake et al, 1995), and
have not been described in normal human skin. Furthermore, Kaplan
et al (1992) found that although CD1a positive dermal DC numbers
increase dramatically following intradermal injection of GM-CSF or
mycobacterial extract, Langerhans cell numbers appeared to be static,
or Langerhans cells were sloughed off during epidermal thickening
(Kaplan et al, 1987). Finally, the turnover of Langerhans cells is very
slow and human Langerhans cells are only gradually replaced by
engrafted cells following bone marrow transplantation (Perreault et al,
1984; Murphy et al, 1986). Therefore, the epidermis does not appear
to be the primary source of DC for repopulation of the dermis, either
during cutaneous immune responses or for steady state turnover of
dermal leukocyte populations.
The majority of dermal DC appear to be recently derived from
blood immigrants rather than epidermal Langerhans cells (Kaplan et al,
1987). There are a number of potential circulating precursors of the
activated dermal DC population described here. Activated dermal DC
may be derived from either a resting or an activated subset of blood
DC (Thomas and Lipsky, 1994; Fearnley et al, 1997) that homes to
dermal T lymphocyte areas. A monocyte derivation for dermal DC is
also possible (Murphy et al, 1986), as there are striking similarities
between dermal DC and monocyte-derived DC (Sallusto and Lanzavec-
chia, 1994). Blood monocytes may develop an activated DC phenotype
under cytokine and tissue-migratory signals. It has also been suggested
that blood contains distinct CD341 precursors of cutaneous lymphocyte
antigen (CLA) negative dermal DC and CLA1 Langerhans cells (Strunk
et al, 1997).
Activation of dermal DC We cannot on the basis of these studies
explain the mechanism for the apparent activation of a subset of dermal
DC. None the less, we can speculate that the observed activated
DC:T lymphocyte aggregates may contribute in several ways towards
cutaneous immunity. Clearly, the activated phenotype of the T
lymphocytes in these clusters raises the possibility that these aggregates
formed upon T lymphocyte recognition of peptide-MHC complexes
on DC, and that we are witnessing an antigen-specific interaction.
This is consistent with the observed expression of the CD86 antigen
found on T lymphocyte-associated dermal DC, but the antigens
involved and the specificity of the T lymphocytes must remain an
enigma until mechanisms to study them evolve.
T lymphocytes may interact with dermal DC in the periphery and
prime antigen laden DC for effective antigen presentation prior to
entry to the lymph node, or even trigger their migration. This may
be especially important for primary antigen epitopes for which only a
low frequency of potential responding naı¨ve T lymphocytes exist. In
support of this, numerous activated DC:T lymphocyte clusters have
been observed in human lymph (Richters et al, 1994; Pope et al, 1995),
especially following application of contact irritants (Brand et al, 1995).
Equally, the activated dermal DC:T lymphocyte clusters observed
may perform a local sentinel function by ensuring rapid responses
following encounter of cutaneous recall antigen. These peripheral
interactions might facilitate the rapid release of T lymphocyte-derived
cytokines and chemotactic factors, resulting in mononuclear cell influx
(Silberberg, 1971; Kaplan et al, 1987). Such a role is consistent with
the dependence of skin immunity on the large number of activated
memory T lymphocytes found in normal human skin, many of which
are known to be DC associated (Bos et al, 1987; Brand et al, 1995;
Pope et al, 1995).
Further analysis of the interactions between dermal DC and T
lymphocytes may be relevant for immunotherapeutic procedures invol-
ving the intradermal administration of primary antigen together with
recall antigens, including helper epitopes.
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